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Pooled Analysis of 6 and I2 month Smoking Abstinence Rates 
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Bupropion (300 mglday) 
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5 6 
Behavioral Therapy 
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53.9 122 27.8 
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1095-54 Radioactive Cigarettes and Corporate Strategy in Light 
of Evidence Derived From Declassified Tobacco 
Industry Documents 
Hrayr S. Karaaueuzian, James Whiting, Cedars-Sinai Medical Center, David G&en 
School of Medicine at UCLA, Los Angeles, CA 
Background: The presence of significant radioactivity in tobacco smoke still remains 
unacknowledged by the tobacco industry (TI). Declassified TI documents shed light oh 
this policy of silence. Methods: All major online soumes of TI documents made available 
by the Minnesota State Attorney General were searched using the terms polonium; 
radioactivity. A total of 56 TI documents and 26 academic publications were selected and 
analyzed. Results: Two sources of tobacco radioactivity have been identified: atmo- 
spheric fallout and soil rich in artificfal fertilizer containing radium, polonium 21OP0, and 
lead 210Pb. The documents show that the TI knew of the presence of significant radioac- 
tivity in tobacco smoke since the early 1950s and had at its disposal all the technical 
means and exoertise needed to measure radioactivity in tobacco leaves and smoke 
(matn & side streams). TI scientists reported 21OPo content of 0.5 pCi/cigarette (i.e., 
0.037 disinteoration oer sec. dos) with 12% of radioactivitv in the main stream and 32% 
in the side stream of the smoke. Since the average daily intake of 2lOPo from food and 
beverages averages 0.1 dps, smokers of one pack (20 cigarettes) a day may intake twice 
the 21OPo activity as nonsmokers. Postmortem findings at the btfurcation of the lower 
lobes of the lung of smokers who died from lung cancer had at least 3 times higher 
PlOPo/g of lung tissue than nonsmokers. Filtering proved ineffective I” 2lOPo removal 
(~0.1%). The concern over the potential hazards of the ionizing alpha particles of 210Po 
in the smoke led TI executives to ban publishing all internal research findings oh radioac- 
tivity. The TI executives found established methods of PO removal using acid treatment 
of tobacco leaves unacceptable because acid media converts ntcotlne base to nicotine 
salt with diminished ability to penetrate the brain causing loss of instant ‘nicotine kick,” 
the documents show. Conclusions: The declassified TI documents show that the industry 
had scientifically accurate knowledge of the presence of radioacbvity in tobacco smoke 
that might promote lung cancer. Adding a warning label oh cigarette packages that 
acknowledges the presence of radioactivity in tobacco smoke seems appropriate. 
1095-55 Additive Benefits of Pravastatin and Aspirin to 
Decrease Risks of Cardiovascular Disease: 
Randomized and Observational Comparisons of 
Secondary Prevention Trials and Their Meta-Analysis 
Charles H. Hennekens, Frank M. Sacks, Andrew Tonkin, Wouter Jukema, Robert P. 
Byington. Bertram Pin, Donald A. Berry, Scott M. Berry, Neville F. Ford, Andrew J. 
Walker, Kannan Natarajan, Chen Sheng-Lln, Frederick T. Fiedorek, Rene Belder, 
University of Miami School of Medicine, Miami, FL 
Background: In randomized trials of secondary prevention, pravastatin and aspirin 
reduce risks of cardiovascular disease (CVD). Pravastatin has a predominantly anti- 
atherogenic effect and aspirin ah immediate anti-platelet effect. Whether they have addi- 
tive clinical benefits has hot been demonstrated. 
Methods: In five randomized thals with pravastatin (40mg), comprising 73,900 patient- 
years of observation, aspirin was also prescribed. We tested whether pravastatin and 
aspihn have additive benefits in the two large trials (LIPID and CARE). We also per- 
formed meta-analyses of these two trials as well as three far smaller angiographic trials 
with clinical endpoktts. In all analyses multivariate models were used to adjust for a large 
number of CVD risk factors 
Results: Both indiwdual trials as well as all meta-analyses demonstrated similar additive 
benefits of pravastatin and aspirin. In meta-analysis the relative risk reductions (RRRs) 
for fatal or non-fatal myocardial infarction (Ml) were 31% for pravastatin plus aspirin ver- 
sus aspirin alone and 26% for pravastatin plus aspirin vemus pravastatin alone. For 
ischemic stroke the corresponding RRRs were 29% and 31%. For the combined ehd- 
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point of coronary heart disease death, non-fatal MI, coronary artery bypass graft, percu- 
taneous transluminal coronary angioplasty or ischemic stroke the RRRs were 24% and 
13%. All RRRs were statistically significant. 
Conclusions: In randomized and observational comparisons of secondary prevention tri- 
als and their meta-analyses there were additive benefits of pravastatin and aspirin in 
reducing risks of CVD. The more widespread and appropriate use of both pravastatin 
and aspirin in secondary prevention of CVD will avoid large numbers of premature 
deaths. 
109556 Do Lipoprotein Subclass Tests Increase Treatment 
Rates in High-Risk Patients? 
Ronald M. Krauss, Soma S. Nag, Shiva G. Sajjan, Thomas W. Weiss, John Brunzell, 
Jere P. Segrest, Leona E. Markson, Charles M. Alexander, Merck & Co.. Inc.. West 
Point, PA 
Background: Although considerable debate surrounds the utility of lipoprotein subclass 
tests versus (vs.) traditional lipid profiles in clinical practice, we are not aware of studies 
on the impact of the availability of lipoprotein subclass tests oh the process of care. 
Methods: A 6.month. randomized, prospective multi-center study evaluated the impact of 
lipoprotein subclass tests (Atherotech) on lipid treatment rates and treatment intensity 
(defined by statin dose and/or the use of combination lipid therapy). Physicians were ran- 
domized to Group A (lipoprotein subclass test results available initially and at 6-months) 
or Group B (traditional lipid values initially and subclass results available only at 6 
months). Untreated, high-risk patients (N=2576) with coronary head disease (CHD), dia- 
betes, or other CHD-risk equivalents were enrolled. There were no protocol-dictated 
requirements for lipid testing or treatment. 
Results: There were 09 Group A vs. 97 Group B physicians. 45% of patients were in 
Group A while 55% were in Group B. Mean age of patients was 64.4 +/- 12.9 years 
(range 16-97) with 47.4% male and 52.6% female. 87.0% were Caucasian, 7.9% were 
African-American, and 5.1% were other raceslethnicities. The results below have not yet 
been adjusted for any differences in baseline charactehstcs. The group provided kpid 
subclass results (A) had higher initial and 6.month lipid treatment rates vs B (initial: 
56.2% “s 51.1%. p=O.Ol; follow-up: A=71.4% vs. B=62.1%; p&0001). In the subgroup 
of patients with baseline LDL >= 100 (ie, needed treatment) who were ieitlally untreated, 
baseline lipid profile values did hot differ significantly; follow-up lipid treatment rates dlf- 
fered significantly (Group A, 44.8% vs. Group B, 33.9% p=O.O02). 
Conclusion: These initial findings suggest that availability of lipoprotein subclass tests in 
these high-risk patients increases treatment rates. The relationship between risk factors 
and baseline characterisbcs. and differences in treatment rates and intensity remain to 
be evaluated. 
1095-57 Adherence to Chronic Therapy Among Patients Treated 
for Hypertension, Dyslipidemia, or Both 
J. Sanford Schwartz. Trent McLaughlin, Deborah Griffts, Amy Arnold, Daniel Pettitt, NDC 
Health, Phoenix, AZ, Pfizer, Inc., New York, NY 
Background: Persistent utilization of medicine in patients wtth concurrent hypertension 
and dyslipidemia is particularly important due to their elevated risk for coronary events. 
The objective of this analysis was to quantify medication adherence for patients receiving 
both an antihypertensive drug (AHD) and lipid regulating therapy (LRD). 
Methods: Retrospective claims analysts using data from several managed care organiza- 
tions (Source: PHARMetrics Integrated Outcomes Database). Patients receiving 
AHD+LRD during 1999-2000 & having -> 1 year of history following the index agent were 
included. Medication possession ratios (MPR) were calculated at P-month intervals to 
assess adherence for the AHD, LRD and AHD + LRD combined. An MPR ~0.80 was 
considered to be indicative of appropriate adherence to medication. 
Results: 5,341 patients were included in the analysis. Over one-thtrd of the sample was 
non-adherent by the end of the second month. While patients tended to be more adher- 
ent with one medication, less than half were adherent with both by month 2, and less 
than one third were adherent to both after one year. 
MPR >0.80 
AHD 
LRD 
AHD + LRD 
Month 
l-2 
66.7% * 
47.7% * 
37.7% 
Month 
3-4 
58.8% ’ 
44.9% * 
35.5% 
Month 
5-6 
56.9% * 
43.6% * 
34.0% 
Month 
7-a 
56.0% * 
42.4% * 
33.2% 
Month 
9-10 
54.7% ’ 
42.0% * 
32.9% 
* p<O.O5 versus AHD+LRD 
Conclusions: The addition of a second aaent is associated with a sianificant reduction I” 
adequate medication adherence, such that less than one third of all patients remain on 
both AHD and LRD by the end of the first year. 
1095-58 Can Changing Referral Patterns Based on ACCIAHA’ 
Practice Guidelines for Coronary Angiography Be 
Measured? Validation of a Decision Analysis Model of 
Test Appropriateness in Coronary Artery Disease 
Patients 
D. Douqlas Miller, Edward J. Dougherty, Debra E. Messinger, Saint Louis University, St. 
Louis, MO 
Background: Despite reimbursement constraints, U.S. coronary angiogtaphy (oath.) 
rates continue to rise. We developed and validated a decision analysis model based oh 
1999 ACC/AHA Guidelines for Coronary Angiography to assess the appropriateness of 
elective cath. to a large Florida health plan (AvMED). 
Methods: A retrospective comparison of Cath. rates & appropriateness was performed 
